SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany
SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany
Explore linked clinical trials.6 results ยท Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| MEK Inhibitor Mirdametinib (PD-0325901) in Patients With Neurofibromatosis Type 1 Associated Plexiform Neurofibromas | Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Neoplasms by Histologic Type, Neoplasms, Nerve Tissue, hereditary disease, hereditary neoplastic syndrome, inherited neurodegenerative disorder, neoplasm, nerve sheath neoplasm, nervous system disorder, neurocutaneous syndrome, neurodegenerative disease, neurofibroma, neurofibromatosis, neurofibromatosis type 1, neuromuscular disease, peripheral nervous system disorder, peripheral nervous system neoplasm, plexiform neurofibroma | Active, not recruiting | Phase 2 | 2026-10-06 | NCT03962543 | |
| SW-682 in Advanced Solid Tumors | Neoplasms by Histologic Type, Neoplasms by Site, Thoracic Neoplasms, adenoma, epithelial neoplasm, lung disorder, lung neoplasm, malignant mesothelioma, mesothelial neoplasm, mesothelioma, neoplasm, pleural neoplasm, respiratory system disorder, respiratory tract neoplasm | Recruiting | Phase 1 | 2026-10-02 | NCT06251310 | |
| A Study of Mirdametinib in Infants and Toddlers With Neurofibromatosis Type 1 Associated Plexiform Neurofibromas | Neurofibromatosis Type 1-Associated Plexiform Neurofibromas | Not yet recruiting | Phase 1 | 2026-09-30 | NCT07850635 | |
| Effect of Hepatic Impairment on the Pharmacokinetics of Mirdametinib | Healthy; Hepatic Impairment | Recruiting | Phase 1 | 2026-09-21 | NCT06997276 | |
| A Study of Nirogacestat in Japanese Adults With Desmoid Tumors/Aggressive Fibromatosis (DT/AF) | Neoplasms by Histologic Type, Neoplasms, Connective and Soft Tissue, Neoplasms, Fibrous Tissue, connective tissue neoplasm, desmoid tumor, fibroma, neoplasm | Active, not recruiting | Phase 2 | 2026-09-15 | NCT07170644 | |
| Nirogacestat in Premenopausal Females With Desmoid Tumor/Aggressive Fibromatosis (DT/AF) | Neoplasms by Histologic Type, Neoplasms, Connective and Soft Tissue, Neoplasms, Fibrous Tissue, connective tissue neoplasm, desmoid tumor, fibroma, neoplasm | Recruiting | Phase 4 | 2026-09-14 | NCT07176689 |